Get the Stockscreener App
999.84
0.15%
-1.51
After Hours:
995.01
-4.83
-0.48%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $999.84, with a volume of 1.43M.
It is down -0.15% in the last 24 hours and down -1.51% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,001.35
Open:
$1000.03
24h Volume:
1.43M
Relative Volume:
0.46
Market Cap:
$892.85B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
44.26
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-0.37%
1M Performance:
-1.51%
6M Performance:
+32.21%
1Y Performance:
+21.33%
1-Day Range:
$990.30
$1,002.93
1-Week Range:
$965.60
$1,012.00
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
999.84 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.99 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.68 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
193.31 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
155.80 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro - Insider Monkey
Lilly Warns Some Medicare GLP-1 Costs Could Exceed $50 - GuruFocus
As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 - Fierce Pharma
Forget Oral Wegovy: This Weight Loss Drug Could Be an Even Bigger Winner - The Motley Fool
Lilly introduces direct-to-employer program for weight-loss drug - Indianapolis Business Journal
Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Eli Lilly to invest $3bn in China in anticipation of orforglipron approval - Pharmaceutical Technology
After touching the $1T club, Eli Lilly CEO David Ricks is making the moves to stay there - Endpoints News
Eli Lilly (LLY) Submits Weight Loss Drug Application in China - GuruFocus
Wolfe bumps Eli Lilly target on oral obesity drug, cardiometabolic portfolio - Investing.com Nigeria
EXCLUSIVE: Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound - Benzinga
Hims & Hers taps ex-Eli Lilly PR chief to lead communications - medwatch.com
Eli Lilly (LLY) to Invest $3B in China for Weight Loss Drug Expa - GuruFocus
Kepler Cheuvreux Suisse SA Invests $3.10 Million in Eli Lilly and Company $LLY - MarketBeat
Bernstein Maintains Outperform on Eli Lilly (LLY) March 2026 - Meyka
Lilly to Invest $3 Billion in China to Boost Obesity Pill - Bloomberg
Eli Lilly and Company $LLY Shares Sold by First Trust Advisors LP - MarketBeat
Financial Life Planners Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly to invest $3 billion in China, seeks approval for weight loss pill - Reuters
Eli Lilly invests USD 500m in South Korean life sciences - medwatch.com
Novo is losing India’s weight-loss market to Eli Lilly. How does it redeem itself? - The Ken
Samsung Biologics, Eli Lilly to launch startup hub in Korea - 매일경제
Hims Hires Ex-Lilly PR Chief as Its Weight-Loss Strategy Shifts - Bloomberg
Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea - BioSpace
Lilly pledges $500M to South Korea biopharma industry, following Roche’s lead - Fierce Biotech
Eli Lilly and Company (LLY) Set to Launch Oral Obesity Drug in Q2, Reuters Reports - Finviz
Bernstein reiterates Eli Lilly stock rating on GLP-1 expansion - Investing.com
Van ECK Associates Corp Purchases 6,260 Shares of Eli Lilly and Company $LLY - MarketBeat
FourThought Financial Partners LLC Increases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Samsung Biologics and Eli Lilly Launch Innovation Hub in Korea - Businesskorea
Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,500 - 富途牛牛
Capital Group Private Client Services Inc. Decreases Stock Position in Eli Lilly and Company $LLY - MarketBeat
Capital International Inc. CA Increases Stake in Eli Lilly and Company $LLY - MarketBeat
Samsung Biologics, Eli Lilly to establish biotech incubator in Incheon - Yonhap News Agency
Eli Lilly and Company (LLY) Announces the Launch of its Employer Connect Platform - Finviz
Eli Lilly to invest $500 mn in S. Korea biotech ecosystem - 매일경제
Eli Lilly to Invest $500M in Korean Biotech Over Five Years - en.sedaily.com
Eli Lilly Expands GLP 1 Reach With New Plants And Wider Coverage - simplywall.st
Eli Lilly GC's Pay Jumps To More Than $9.8M In 2025 - Law360
Should you buy Eli Lilly stock now or wait for more of a pullback? - MSN
Stock Awards Pump Up Pay for Eli Lilly GC - Law.com
Eli Lilly (LLY) Is Making a Big Bet on South Korea’s Biotech Sector. Here’s Why - TipRanks
NVIDIA Upgraded, Eli Lilly Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Actos Class Action Puts Eli Lilly Legal And Cash Flow Risks In Focus - Yahoo Finance UK
Schroder Investment Management Trims Stake in Eli Lilly - National Today
Eli Lilly says some Medicare plans may exceed $50 cap for weight-loss drugs - Reuters
Eli Lilly (LLY) Announces Expanded Access to Obesity Medications - GuruFocus
Updated: Lilly’s Statement on the CMMI BALANCE Model for GLP-1 Medicines and Medicare GLP-1 Bridge Model - Eli Lilly
Russell Investments Boosts Stake in Eli Lilly - National Today
Eli Lilly Picks Korea for $500M Innovation Hub After U.S., China - en.sedaily.com
LGT Fund Management Co Ltd. Sells 6,686 Shares of Eli Lilly and Company - National Today
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):